

**In the matter of the Canadian Anti-Doping Program;**

**And in the matter of an anti-doping rule violation by Stavros Katsantonis asserted  
by the Canadian Centre for Ethics in Sport;**

File Outcome Summary

**Summary**

1. The Canadian Centre for Ethics in Sport (CCES) conducted an out of competition sample collection session on March 22, 2019, in Toronto, ON.
2. Mr. Stavros Katsantonis (“the athlete”) was selected for doping control. The sample provided by the athlete returned an adverse finding for SARM LGD-4033, a prohibited substance.
3. Following receipt of the CCES’ assertion of an anti-doping rule violation for the presence of SARM LGD-4033, the athlete accepted the anti-doping rule violation and waived his right to a hearing.

**Jurisdiction**

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and carries out the CADP, including providing anti-doping services to national sport organizations and their members.
5. As Canada’s national anti-doping organization, the CCES is in compliance with the World Anti-Doping Code (Code) and its mandatory International Standards. The CCES has implemented the Code and its mandatory International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The athlete is a member of U SPORTS, and participates in the sport of Football. According to Part C, Rule 1.3 of the CADP, the CADP provisions apply to all members of, and participants in the activities of, sport organizations adopting it. The CADP was issued for adoption by Canadian sport organizations on October 1, 2014, to be operational on January 1, 2015. U SPORTS adopted the CADP on December 19, 2014. Therefore, as a member of U SPORTS and/or as a participant in U SPORTS sport activities, the athlete is subject to the Rules of the CADP.

**Doping Control**

7. On March 22, 2019, the CCES conducted an out of competition doping control session in Toronto, ON. Testing was conducted on U SPORTS athletes as part of the CCES’ domestic test distribution plan, all pursuant to the CADP.

8. The athlete was notified for doping control and, together with the Doping Control Officer (DCO) from the CCES, completed the sample collection process. The athlete's sample code number was 4317321.
9. On March 26, 2019, the athlete's sample was received by World Anti-Doping Agency (WADA) accredited laboratory, the INRS-Institut Armand-Frappier (INRS), in Laval, QC.

### **Results Management**

10. The adverse analytical finding was received from the INRS on April 9, 2019. The Certificate of Analysis indicated the presence of SARM LGD-4033.
11. SARM LGD-4033 is classified as a prohibited substance on the 2019 WADA Prohibited List.
12. On April 18, 2019, the CCES formally asserted a violation against the athlete for the presence of a prohibited substance. A mandatory Provisional Suspension was also imposed against the athlete on this date.
13. In accordance with CADP Rule 10.2.1, the standard sanction for an intentional doping violation involving the presence of a prohibited substance (non-specified substance), is a four (4) year period of ineligibility. The CCES proposed the standard four (4) year sanction within its assertion of April 18, 2019.

### **Confirmation of Violation and Sanction**

14. On May 2, 2019, in response to the CCES' assertion, the athlete waived his right to a hearing thereby accepting both the asserted violation and the four (4) year period of ineligibility proposed by the CCES.
15. In accordance with CADP Rules 7.9.1 and 10.11 the athlete's period of ineligibility will formally conclude on April 17, 2023.
16. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 21<sup>st</sup> day of May 2019.



---

Jeremy Luke  
Senior Director, Sport Integrity  
CCES